GILD - Acceleron's sotatercept shows positive action in mid-stage pulmonary arterial hypertension studies

Acceleron Pharma ([[XLRN]] -1.8%) announces new data from two Phase 2 clinical trials, SPECTRA and PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension ((PAH)).Preliminary results from 10 participants in SPECTRA showed that treated patients experienced substantial improvements in a range of hemodynamic measures and exercise tolerance/capacity. Of note was almost a 36% drop in pulmonary vascular resistance, a metric for resistance against blood flow from the pulmonary artery to the heart's left atrium.New cardiac and pulmonary function data from PULSAR showed improvements in right ventricular-pulmonary arterial (RV-PA) coupling, which represents the match between the output of the right ventricle ((RV)) and the resistance of the pulmonary vasculature, and RV function. In January, the company announced that the study met the primary endpoint.A 284-subject Phase 3 trial, STELLAR, should launch next month. The primary endpoint will be the change from baseline to week 24 in the 6-minute walk test.Sotatercept is

For further details see:

Acceleron's sotatercept shows positive action in mid-stage pulmonary arterial hypertension studies